. To study potential therapeutic effects of ST266, EAE was induced on day 0 (a), and intranasal ST266 treatment was initiated at the peak of optic nerve inflammation (b), midpoint of axon injury and demyelination (c), or onset of RGC loss (d). All mice were sacrificed after RGC loss is essentially complete (e). Relative demyelination levels in spinal cords of PBS-treated EAE mice are not significantly different from ST266-treated EAE mice. E-G. EAE mice (N=6/treatment group) were treated with one intranasal drop of PBS or ST266 daily beginning 15 days post-immunization. ST266 was given on indicated days (15-42; 15-30; 22-42; or 30-42) for each treatment group, and PBS was given on all other days until mice were euthanized on day 42. E. Relative inflammation levels in spinal cords of PBS-treated EAE mice are not significantly different from ST266-treated EAE mice. F. Relative demyelination levels in spinal cords of PBS-treated EAE mice are not significantly different from ST266-treated EAE mice. G. Variations in EAE scores between the four different ST266-treatment groups and the PBS-treated EAE mice were not statistically significant.
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